AtaiBeckley attracted co-development and royalty offers before $2.8B Lilly deal
More details have emerged about how the industry’s largest psychedelic biotech buyout came to fruition. In an SEC filing on Thursday morning, AtaiBeckley disclosed some of the play-by-play from its
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.